内容紹介
Efficacy of Sorafenib versus Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization
Summary
We compared the benefits of sorafenib with that of hepatic arterial infusion chemotherapy(HAIC)for advanced hepatocellular carcinoma(ad-HCC)refractory to transcatheter arterial chemoembolization(TACE). We evaluated the patient characteristics, the median survival time(MST), and the prognostic factors in 17 patients in the sorafenib group and in 26 patients in the HAIC group. No significant difference was observed in the patient characteristics between the groups. The MST in the sorafenib group and HAIC group was 483 days and 284 days, respectively. A significantly longer survival time was noted in the sorafenib group(p=0.033). The prognostic factors were sorafenib therapy in all 43 patients(hazard ratio: 3.32[95%CI: 1.36-8.10], p=0.008)and the longer treatment period of sorafenib in the sorafenib group(hazard ratio: 0.99[95%CI: 0.984-0.999], p=0.009). When compared with HAIC, sorafenib showed favorable treatment results in patients with ad-HCC refractory to TACE.
要旨
当院において肝動脈化学塞栓術(TACE)不応と判断し,ソラフェニブまたはリザーバー持続肝動注化学療法(HAIC)が選択された進行肝細胞癌(ad-HCC)症例を比較し,TACE不応後のソラフェニブ導入の有効性について検討した。対象はTACE不応と判断され,ソラフェニブ単独またはソラフェニブとHAICが併用されたソラフェニブ群17例,HAIC単独群26例で,各群における背景因子,累積生存率,予後規定因子について統計学的に比較検討した。背景因子については両群間に有意差は認めず,生存期間はソラフェニブ群において有意に延長を認めた(p=0.033)。予後規定因子として全43例においてソラフェニブ投与例,ソラフェニブ群では長期投与例が選択された。ソラフェニブの導入により,TACE不応ad-HCCの予後延長が期待できる可能性が示唆された。
目次
Summary
We compared the benefits of sorafenib with that of hepatic arterial infusion chemotherapy(HAIC)for advanced hepatocellular carcinoma(ad-HCC)refractory to transcatheter arterial chemoembolization(TACE). We evaluated the patient characteristics, the median survival time(MST), and the prognostic factors in 17 patients in the sorafenib group and in 26 patients in the HAIC group. No significant difference was observed in the patient characteristics between the groups. The MST in the sorafenib group and HAIC group was 483 days and 284 days, respectively. A significantly longer survival time was noted in the sorafenib group(p=0.033). The prognostic factors were sorafenib therapy in all 43 patients(hazard ratio: 3.32[95%CI: 1.36-8.10], p=0.008)and the longer treatment period of sorafenib in the sorafenib group(hazard ratio: 0.99[95%CI: 0.984-0.999], p=0.009). When compared with HAIC, sorafenib showed favorable treatment results in patients with ad-HCC refractory to TACE.
要旨
当院において肝動脈化学塞栓術(TACE)不応と判断し,ソラフェニブまたはリザーバー持続肝動注化学療法(HAIC)が選択された進行肝細胞癌(ad-HCC)症例を比較し,TACE不応後のソラフェニブ導入の有効性について検討した。対象はTACE不応と判断され,ソラフェニブ単独またはソラフェニブとHAICが併用されたソラフェニブ群17例,HAIC単独群26例で,各群における背景因子,累積生存率,予後規定因子について統計学的に比較検討した。背景因子については両群間に有意差は認めず,生存期間はソラフェニブ群において有意に延長を認めた(p=0.033)。予後規定因子として全43例においてソラフェニブ投与例,ソラフェニブ群では長期投与例が選択された。ソラフェニブの導入により,TACE不応ad-HCCの予後延長が期待できる可能性が示唆された。